Aligos Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(Unaudited)
(In thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue from collaborations | $— | $292 |
| Revenue from customers | 311 | 694 |
| Operating expenses: | ||
| Research and development | 14,502 | 16,366 |
| General and administrative | 5,052 | 6,666 |
| Total operating expenses | 19,554 | 23,032 |
| Loss from operations | (19,243) | (22,046) |
| Interest and other income, net | 880 | 1,579 |
| Change in fair value of 2023 common warrants | 61,494 | (14,372) |
| Income (loss) before income tax | 43,131 | (34,839) |
| Income tax provision | (43) | (24) |
| Net income (loss) | 43,088 | (34,863) |
| Other comprehensive loss: | ||
| Unrealized loss on available-for-sale securities | (4) | (69) |
| Other comprehensive loss | (4) | (69) |
| Comprehensive income (loss) | $43,084 | $(34,932) |
| Net income (loss) per share, basic | $5.12 | $(5.58) |
| Net loss per share, diluted | $(2.11) | $(5.58) |
| Weighted average shares of common stock, basic | 8,408,481 | 6,246,113 |
| Weighted average shares of common stock, diluted | 8,709,693 | 6,246,113 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.